182 related articles for article (PubMed ID: 22059385)
1. Inhibition mechanism of human galectin-7 by a novel galactose-benzylphosphate inhibitor.
Masuyer G; Jabeen T; Öberg CT; Leffler H; Nilsson UJ; Acharya KR
FEBS J; 2012 Jan; 279(2):193-202. PubMed ID: 22059385
[TBL] [Abstract][Full Text] [Related]
2. Benzimidazole-galactosides bind selectively to the Galectin-8 N-Terminal domain: Structure-based design and optimisation.
Hassan M; van Klaveren S; Håkansson M; Diehl C; Kovačič R; Baussière F; Sundin AP; Dernovšek J; Walse B; Zetterberg F; Leffler H; Anderluh M; Tomašič T; Jakopin Ž; Nilsson UJ
Eur J Med Chem; 2021 Nov; 223():113664. PubMed ID: 34225180
[TBL] [Abstract][Full Text] [Related]
3. Enzymatic synthesis of non-natural trisaccharides and galactosides; Insights of their interaction with galectins as a function of their structure.
Porciúncula González C; Cagnoni AJ; Mariño KV; Fontana C; Saenz-Méndez P; Irazoqui G; Giacomini C
Carbohydr Res; 2019 Jan; 472():1-15. PubMed ID: 30428394
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of multivalent galactose-based dendrimer recognition by human galectin-7.
Ramaswamy S; Sleiman MH; Masuyer G; Arbez-Gindre C; Micha-Screttas M; Calogeropoulou T; Steele BR; Acharya KR
FEBS J; 2015 Jan; 282(2):372-87. PubMed ID: 25367374
[TBL] [Abstract][Full Text] [Related]
5. Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors.
Hsieh TJ; Lin HY; Tu Z; Lin TC; Wu SC; Tseng YY; Liu FT; Hsu ST; Lin CH
Sci Rep; 2016 Jul; 6():29457. PubMed ID: 27416897
[TBL] [Abstract][Full Text] [Related]
6. Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin.
Vladoiu MC; Labrie M; Létourneau M; Egesborg P; Gagné D; Billard É; Grosset AA; Doucet N; Chatenet D; St-Pierre Y
Oncotarget; 2015 Dec; 6(38):40970-80. PubMed ID: 26543238
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Design of a Monosaccharide Ligand Targeting Galectin-8.
Bohari MH; Yu X; Kishor C; Patel B; Go RM; Eslampanah Seyedi HA; Vinik Y; Grice ID; Zick Y; Blanchard H
ChemMedChem; 2018 Aug; 13(16):1664-1672. PubMed ID: 29926535
[TBL] [Abstract][Full Text] [Related]
8. X-ray structure of a protease-resistant mutant form of human galectin-9 having two carbohydrate recognition domains with a metal-binding site.
Yoshida H; Nishi N; Wada K; Nakamura T; Hirashima M; Kuwabara N; Kato R; Kamitori S
Biochem Biophys Res Commun; 2017 Sep; 490(4):1287-1293. PubMed ID: 28687490
[TBL] [Abstract][Full Text] [Related]
9. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model.
Stannard KA; Collins PM; Ito K; Sullivan EM; Scott SA; Gabutero E; Darren Grice I; Low P; Nilsson UJ; Leffler H; Blanchard H; Ralph SJ
Cancer Lett; 2010 Dec; 299(2):95-110. PubMed ID: 20826047
[TBL] [Abstract][Full Text] [Related]
10. Galectin-13, a different prototype galectin, does not bind β-galacto-sides and forms dimers via intermolecular disulfide bridges between Cys-136 and Cys-138.
Su J; Wang Y; Si Y; Gao J; Song C; Cui L; Wu R; Tai G; Zhou Y
Sci Rep; 2018 Jan; 8(1):980. PubMed ID: 29343868
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the Structure-Activity Relationship of Galectin-Ligand Interactions.
Chan YC; Lin HY; Tu Z; Kuo YH; Hsu SD; Lin CH
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382172
[TBL] [Abstract][Full Text] [Related]
12. A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
Rajput VK; MacKinnon A; Mandal S; Collins P; Blanchard H; Leffler H; Sethi T; Schambye H; Mukhopadhyay B; Nilsson UJ
J Med Chem; 2016 Sep; 59(17):8141-7. PubMed ID: 27500311
[TBL] [Abstract][Full Text] [Related]
13. Quinoline-galactose hybrids bind selectively with high affinity to a galectin-8 N-terminal domain.
Pal KB; Mahanti M; Huang X; Persson S; Sundin AP; Zetterberg FR; Oredsson S; Leffler H; Nilsson UJ
Org Biomol Chem; 2018 Aug; 16(34):6295-6305. PubMed ID: 30117507
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the Molecular Details of the Interactions of Selenoglycosides and Human Galectin-3.
Raics M; Balogh ÁK; Kishor C; Timári I; Medrano FJ; Romero A; Go RM; Blanchard H; Szilágyi L; E Kövér K; Fehér K
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269646
[TBL] [Abstract][Full Text] [Related]
15. Affinity of galectin-8 and its carbohydrate recognition domains for ligands in solution and at the cell surface.
Carlsson S; Oberg CT; Carlsson MC; Sundin A; Nilsson UJ; Smith D; Cummings RD; Almkvist J; Karlsson A; Leffler H
Glycobiology; 2007 Jun; 17(6):663-76. PubMed ID: 17339281
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of galectins with small molecules.
Oberg CT; Leffler H; Nilsson UJ
Chimia (Aarau); 2011; 65(1-2):18-23. PubMed ID: 21469439
[TBL] [Abstract][Full Text] [Related]
17. Saturation Transfer Difference NMR and Molecular Docking Interaction Study of Aralkyl-Thiodigalactosides as Potential Inhibitors of the Human-Galectin-3 Protein.
Hőgye F; Farkas LB; Balogh ÁK; Szilágyi L; Alnukari S; Bajza I; Borbás A; Fehér K; Illyés TZ; Timári I
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339036
[TBL] [Abstract][Full Text] [Related]
18. Efficient synthesis of a galectin inhibitor clinical candidate (TD139) using a Payne rearrangement/azidation reaction cascade.
St-Gelais J; Denavit V; Giguère D
Org Biomol Chem; 2020 May; 18(20):3903-3907. PubMed ID: 32400847
[TBL] [Abstract][Full Text] [Related]
19. Regioselective 3-O-Substitution of Unprotected Thiodigalactosides: Direct Route to Galectin Inhibitors.
Vašíček T; Spiwok V; Červený J; Petrásková L; Bumba L; Vrbata D; Pelantová H; Křen V; Bojarová P
Chemistry; 2020 Aug; 26(43):9620-9631. PubMed ID: 32368810
[TBL] [Abstract][Full Text] [Related]
20. Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives.
Téllez-Sanz R; García-Fuentes L; Vargas-Berenguel A
Curr Med Chem; 2013; 20(24):2979-90. PubMed ID: 23834183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
